Kevin Davis, MD
Infectious Disease · Fort Smith, ARNPI 1033452990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $741, more than ten times the $15 reported in 2019.
Across 83 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$412
- Viiv Healthcare Company$411
- Insmed, Inc.$333
- Astellas Pharma US Inc$157
- AstraZeneca$122
- Paratek Pharmaceuticals, Inc.$94
- plus $476 from 11 others
What the payments were for
- Food & beverage$1,85192%
- Education$1548%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $412 |
| Viiv Healthcare Company | 20 | $411 |
| Insmed, Inc. | 17 | $333 |
| Astellas Pharma US Inc | 4 | $157 |
| AstraZeneca(2 entities) | 7 | $122 |
| Paratek Pharmaceuticals, Inc. | 4 | $94 |
| Pfizer | 6 | $92 |
| AbbVie | 3 | $76 |
| Melinta Therapeutics, LLC | 4 | $74 |
| Merck | 3 | $60 |
| Boehringer Ingelheim | 2 | $42 |
| Novo Nordisk | 2 | $31 |
| Amgen(2 entities) | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$259
How this compares
$2,005 in reported general payments places this provider in the 85th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 150 | $597,012 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 30 | $465,268 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 23 | $105,879 |
| Daptomycin | 77 | $75,062 |
| TivicayDolutegravir Sodium | 14 | $31,604 |
| PrezcobixDarunavir/Cobicistat | 13 | $31,356 |
| IsentressRaltegravir Potassium | 13 | $25,439 |
| ErtapenemErtapenem Sodium | 39 | $18,379 |
| CeftriaxoneCeftriaxone Sodium | 131 | $15,894 |
| Rifabutin | 15 | $12,925 |
| EliquisApixaban | 17 | $10,227 |
| Voriconazole | 36 | $9,601 |
| Rifampin | 44 | $5,045 |
| Itraconazole | 20 | $4,526 |
| Ethambutol Hcl | 66 | $3,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $412 | $597,012150 claims |
| Insmed, Inc.Arikayce | $333 | $465,26830 claims |
| Viiv Healthcare CompanyTivicay | $411 | $31,60414 claims |
| MerckIsentress | $60 | $25,43913 claims |
| PfizerEliquis | $92 | $10,22717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 36 infectious disease providers in Arkansas.
Other infectious disease in Fort Smith
- Mark StillwellFort Smith$795
- Raed KhairyFort Smith$39
- Daniel YoungBentonville$65K
- James NewtonFayetteville$15K
- Stephen HenniganFayetteville$9K
- Andrew EbersRogers$2K
- Jeremy BariolaLittle Rock$2K
- Naveen PatilLittle Rock$1K
- Amanda NovackNorth Little Rock$1K
- Katherine FerrenLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.